Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective

With the growth of aging population all over the world, a rising incidence of Alzheimer's disease (AD) has been recently observed. In contrast to FDA-approved western drugs, herbal medicines, featured as abundant ingredients and multi-targeting, have been acknowledged with notable anti-AD effects although the mechanism of action (MOA) is unknown. Investigating the possible MOA for these herbs can not only refresh but also extend the current knowledge of AD pathogenesis. In this study, clinically tested anti-AD herbs, their ingredients as well as their corresponding target proteins were systematically reviewed together with applicable bioinformatics resources and methodologies. Based on above information and resources, we present a systematically target network analysis framework to explore the mechanism of anti-AD herb ingredients. Our results indicated that, in addition to the binding of those symptom-relieving targets as the FDA-approved drugs usually do, ingredients of anti-AD herbs also interact closely with a variety of successful therapeutic targets related to other diseases, such as inflammation, cancer and diabetes, suggesting the possible cross-talks between these complicated diseases. Furthermore, pathways of Ca(2+) equilibrium maintaining upstream of cell proliferation and inflammation were densely targeted by the anti-AD herbal ingredients with rigorous statistic evaluation. In addition to the holistic understanding of the pathogenesis of AD, the integrated network analysis on the MOA of herbal ingredients may also suggest new clues for the future disease modifying strategies.

[1]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[2]  S. Stahl Cholinesterase inhibitors for Alzheimer's disease. , 1998, Hospital practice.

[3]  G. Church,et al.  Systematic determination of genetic network architecture , 1999, Nature Genetics.

[4]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[5]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[6]  Dmitrij Frishman,et al.  MIPS: a database for genomes and protein sequences , 2000, Nucleic Acids Res..

[7]  P. Rossini,et al.  Movement-Related Electroencephalographic Reactivity in Alzheimer Disease , 2000, NeuroImage.

[8]  R. K. Gordon,et al.  The NMDA receptor ion channel: a site for binding of huperzine A , 2001, Journal of applied toxicology : JAT.

[9]  P. Schultz,et al.  The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[11]  Zhenxin Zhang,et al.  [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. , 2002, Zhonghua yi xue za zhi.

[12]  Ioannis Xenarios,et al.  DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions , 2002, Nucleic Acids Res..

[13]  P. Butko,et al.  Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2004, Nucleic Acids Res..

[15]  Sanjeev Banerjee,et al.  Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. , 2003, Cancer research.

[16]  Yu Zong Chen,et al.  Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.

[17]  E. Perry,et al.  Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial , 2003, Pharmacology Biochemistry and Behavior.

[18]  Yung-Hyun Choi,et al.  Induction of Bax and activation of caspases during beta-sitosterol-mediated apoptosis in human colon cancer cells. , 2003, International journal of oncology.

[19]  Sanjeev Banerjee,et al.  Ursolic Acid Inhibits Nuclear Factor-κB Activation Induced by Carcinogenic Agents through Suppression of IκBα Kinase and p65 Phosphorylation: Correlation with Down-Regulation of Cyclooxygenase 2, Matrix Metalloproteinase 9, and Cyclin D1 , 2003 .

[20]  J. Quinn,et al.  Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. , 2004, Human molecular genetics.

[21]  L. Leung,et al.  Effect of dietary flavonols on oestrogen receptor transactivation and cell death induction. , 2004, The British journal of nutrition.

[22]  J. Eu,et al.  Reperfusion injury in skeletal muscle is reduced in inducible nitric oxide synthase knockout mice. , 2004, Journal of applied physiology.

[23]  K. Sneppen,et al.  Detection of topological patterns in complex networks: correlation profile of the internet , 2002, cond-mat/0205379.

[24]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[25]  P. Reddy,et al.  Can herbs provide a new generation of drugs for treating Alzheimer's disease? , 2005, Brain Research Reviews.

[26]  A. Bråthe,et al.  6‐Substituted Purines as Inhibitors of 15‐Lipoxygenase; a Structure‐Activity Study , 2005, Archiv der Pharmazie.

[27]  J. Miller,et al.  Alzheimer disease and cancer , 2005, Neurology.

[28]  Di Chen,et al.  Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. , 2005, Biochemical pharmacology.

[29]  D. M. Robinson,et al.  Memantine , 2012, Drugs.

[30]  Y. Christen,et al.  Amyloid-β-Induced Pathological Behaviors Are Suppressed by Ginkgo biloba Extract EGb 761 and Ginkgolides in Transgenic Caenorhabditis elegans , 2006, The Journal of Neuroscience.

[31]  I. Raskin,et al.  Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus. , 2006, Phytochemistry.

[32]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[33]  Rui Wang,et al.  Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor , 2006, Acta Pharmacologica Sinica.

[34]  Christian Blaschke,et al.  Status of text-mining techniques applied to biomedical text. , 2006, Drug discovery today.

[35]  H. Zhou,et al.  Traditional Chinese medicine information database , 2005, Journal of ethnopharmacology.

[36]  J. Morris,et al.  ADCS Prevention Instrument Project: ADCS-Clinicians' Global Impression of Change Scales (ADCS-CGIC), Self-rated and Study Partner-rated Versions , 2006, Alzheimer disease and associated disorders.

[37]  P. Bria,et al.  Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study , 2006, European journal of neurology.

[38]  Changyu Shen,et al.  Mining Alzheimer Disease Relevant Proteins from Integrated Protein Interactome Data , 2005, Pacific Symposium on Biocomputing.

[39]  Iulian Lancu,et al.  [The minimental state examination--an up-to-date review]. , 2006, Harefuah.

[40]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[41]  Chin-Lin Hsu,et al.  Gallic acid induces apoptosis in 3T3-L1 pre-adipocytes via a Fas- and mitochondrial-mediated pathway. , 2007, Journal of agricultural and food chemistry.

[42]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[43]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[44]  M. Kawai,et al.  Flavonoids and related compounds as anti-allergic substances. , 2007, Allergology international : official journal of the Japanese Society of Allergology.

[45]  Hyung Keun Kim,et al.  Down-regulation of iNOS and TNF-alpha expression by kaempferol via NF-kappaB inactivation in aged rat gingival tissues. , 2007, Biogerontology.

[46]  E. Wouters,et al.  Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. , 2007, The Journal of nutrition.

[47]  C. Luckhaus,et al.  Estrogen Receptor 1 gene (ESR1) variants in Alzheimer’s disease. Results of a meta-analysis , 2007, Aging clinical and experimental research.

[48]  Y. Zhang,et al.  IntAct—open source resource for molecular interaction data , 2006, Nucleic Acids Res..

[49]  R. Hayeshi,et al.  The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. , 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[50]  H. Kitano A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[51]  Maria Victoria Schneider,et al.  MINT: a Molecular INTeraction database. , 2002, FEBS letters.

[52]  Hyung Keun Kim,et al.  Down-regulation of iNOS and TNF-α expression by kaempferol via NF-κB inactivation in aged rat gingival tissues , 2007, Biogerontology.

[53]  I. Melnikova Therapies for Alzheimer's disease , 2007, Nature Reviews Drug Discovery.

[54]  H. Lim,et al.  Inhibition of Mammalian Collagenase, Matrix Metalloproteinase-1, by Naturally-Occurring Flavonoids , 2007, Planta medica.

[55]  K. Wesnes Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System , 2008, Neurodegenerative Diseases.

[56]  C. Colton,et al.  The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. , 2008, Journal of Alzheimer's disease : JAD.

[57]  D. Geschwind,et al.  A Systems Level Analysis of Transcriptional Changes in Alzheimer's Disease and Normal Aging , 2008, The Journal of Neuroscience.

[58]  P. Aisen,et al.  An update on huperzine A as a treatment for Alzheimer's disease , 2008, Expert opinion on investigational drugs.

[59]  Linhao Li,et al.  Bioactive Terpenoids and Flavonoids from Ginkgo Biloba Extract Induce the Expression of Hepatic Drug-Metabolizing Enzymes Through Pregnane X Receptor, Constitutive Androstane Receptor, and Aryl hydrocarbon Receptor-Mediated Pathways , 2009, Pharmaceutical Research.

[60]  T. Wisniewski,et al.  5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  Xiangnian Fang,et al.  Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity. , 2008, Life sciences.

[62]  R. Martins,et al.  Association of alleles carried at TNFA -850 and BAT1 -22 with Alzheimer's disease , 2008, Journal of Neuroinflammation.

[63]  C. Lendon,et al.  A common biological mechanism in cancer and Alzheimer's disease? , 2009, Current Alzheimer research.

[64]  P. Truffinet,et al.  Pertinence des critères d’évaluation utilisés dans les essais cliniques sur la maladie d’Alzheimer , 2009 .

[65]  S. Ekins,et al.  Predicting Inhibitors of Acetylcholinesterase by Regression and Classification Machine Learning Approaches with Combinations of Molecular Descriptors , 2009, Pharmaceutical Research.

[66]  Jin-Tai Yu,et al.  Calcium dysregulation in Alzheimer's disease: From mechanisms to therapeutic opportunities , 2009, Progress in Neurobiology.

[67]  Xiaoyan Zhu,et al.  Building Disease-Specific Drug-Protein Connectivity Maps from Molecular Interaction Networks and PubMed Abstracts , 2009, PLoS Comput. Biol..

[68]  Allan Jones,et al.  Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. , 2009, Journal of Alzheimer's disease : JAD.

[69]  M. Yassuda,et al.  Short cognitive performance test: diagnostic accuracy and education bias in older Brazilian adults. , 2009, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[70]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[71]  D. Butterfield,et al.  Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. , 2009, The Journal of nutritional biochemistry.

[72]  J. Ménard,et al.  Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. , 2009, Therapie.

[73]  Nanda Ghoshal,et al.  Hybrid Structure-Based Virtual Screening Protocol for the Identification of Novel BACE1 Inhibitors , 2009, J. Chem. Inf. Model..

[74]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[75]  Masaru Tomita,et al.  Network features and pathway analyses of a signal transduction cascade , 2009, Frontiers Neuroinformatics.

[76]  Peng Jiang,et al.  Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..

[77]  Ivan V. Goussakov,et al.  NMDA-Mediated Ca2+ Influx Drives Aberrant Ryanodine Receptor Activation in Dendrites of Young Alzheimer's Disease Mice , 2010, The Journal of Neuroscience.

[78]  K. Ramana,et al.  Aldose reductase: a novel therapeutic target for inflammatory pathologies. , 2010, The international journal of biochemistry & cell biology.

[79]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[80]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[81]  Roded Sharan,et al.  An Algorithmic Framework for Predicting Side-Effects of Drugs , 2010, RECOMB.

[82]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[83]  Leming Shi,et al.  Identifying Unexpected Therapeutic Targets via Chemical-Protein Interactome , 2010, PloS one.

[84]  L. Rangel-Ordóñez,et al.  Plasma Levels and Distribution of Flavonoids in Rat Brain after Single and Repeated Doses of Standardized Ginkgo biloba Extract EGb 761® , 2010, Planta medica.

[85]  C. Tsai,et al.  Evaluation of the poly(ADP‐ribose) polymerase‐1 gene variants in Alzheimer's disease , 2010, Journal of clinical laboratory analysis.

[86]  N. Faux,et al.  A domain level interaction network of amyloid precursor protein and Aβ of Alzheimer's disease , 2010, Proteomics.

[87]  M. Citron Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[88]  Xue-Gang Yang,et al.  In silico prediction and screening of γ‐secretase inhibitors by molecular descriptors and machine learning methods , 2009, J. Comput. Chem..

[89]  F. LaFerla Pathways linking Abeta and tau pathologies. , 2010, Biochemical Society transactions.

[90]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[91]  K. Ramana Aldose reductase: new insights for an old enzyme , 2011, Biomolecular concepts.

[92]  G. Hu,et al.  An integrated genetics approach for identifying protein signal pathways of Alzheimer's disease , 2011, Computer methods in biomechanics and biomedical engineering.

[93]  S. Mathur,et al.  Drug repositioning using disease associated biological processes and network analysis of drug targets. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[94]  Z. Al-Rashid,et al.  (+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase. , 2011, Bioorganic & medicinal chemistry letters.

[95]  V. D. da Silva,et al.  In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity. , 2011, Future medicinal chemistry.

[96]  Xiaohua Hu,et al.  Exploring matrix factorization techniques for significant genes identification of Alzheimer’s disease microarray gene expression data , 2011, BMC Bioinformatics.

[97]  Hao Ye,et al.  HIT: linking herbal active ingredients to targets , 2010, Nucleic Acids Res..

[98]  M. Rosales-Hernández,et al.  In silico methods to assist drug developers in acetylcholinesterase inhibitor design. , 2011, Current medicinal chemistry.

[99]  M. Bajda,et al.  Multi-target-directed ligands in Alzheimer's disease treatment. , 2011, Current medicinal chemistry.

[100]  Doheon Lee,et al.  Building the process-drug–side effect network to discover the relationship between biological Processes and side effects , 2011, BMC Bioinformatics.

[101]  P. Bork,et al.  Network Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity , 2011, PloS one.

[102]  Zhiwei Cao,et al.  Insight into potential toxicity mechanisms of melamine: an in silico study. , 2011, Toxicology.

[103]  M. Furey The prominent role of stimulus processing: cholinergic function and dysfunction in cognition. , 2011, Current opinion in neurology.

[104]  H. Manev,et al.  Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[105]  Xia Li,et al.  The expanded human disease network combining protein–protein interaction information , 2011, European Journal of Human Genetics.

[106]  F. Salawu,et al.  Alzheimer's disease: a review of recent developments. , 2011, Annals of African medicine.

[107]  Keun Woo Lee,et al.  Potent bace-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies , 2011, BMC Bioinformatics.

[108]  Gareth Williams A searchable cross-platform gene expression database reveals connections between drug treatments and disease , 2012, BMC Genomics.

[109]  M. Totrov,et al.  Triazole-linked reduced amide isosteres: an approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[110]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[111]  M. Zehl,et al.  Catechol alkenyls from Semecarpus anacardium: acetylcholinesterase inhibition and binding mode predictions. , 2012, Journal of ethnopharmacology.

[112]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[113]  Christie S. Chang,et al.  The BioGRID interaction database: 2013 update , 2012, Nucleic Acids Res..